Business Description
HAEMATO AG
ISIN : DE000A289VV1
Compare
Compare
Traded in other countries / regions
HAEK.Germany0VZ7.UK IPO Date
2006-08-18Description
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.45 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.2 | |||||
| Interest Coverage | 15.83 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.74 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -18.1 | |||||
| 3-Year EBITDA Growth Rate | 52.8 | |||||
| 3-Year Book Growth Rate | -3.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.87 | |||||
| 9-Day RSI | 59.17 | |||||
| 14-Day RSI | 51.33 | |||||
| 6-1 Month Momentum % | -15 | |||||
| 12-1 Month Momentum % | -3.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.46 | |||||
| Quick Ratio | 1.66 | |||||
| Cash Ratio | 0.83 | |||||
| Days Inventory | 37.68 | |||||
| Days Sales Outstanding | 25.39 | |||||
| Days Payable | 23.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 7.14 | |||||
| Dividend Payout Ratio | 0.86 | |||||
| 3-Year Dividend Growth Rate | -28.4 | |||||
| Forward Dividend Yield % | 7.14 | |||||
| 5-Year Yield-on-Cost % | 7.14 | |||||
| 3-Year Average Share Buyback Ratio | -31.8 | |||||
| Shareholder Yield % | 7.92 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 7.57 | |||||
| Operating Margin % | 3.52 | |||||
| Net Margin % | 3.69 | |||||
| FCF Margin % | 3.93 | |||||
| ROE % | 6.52 | |||||
| ROA % | 5.42 | |||||
| ROIC % | 5.5 | |||||
| ROC (Joel Greenblatt) % | 57.7 | |||||
| ROCE % | 8.58 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.17 | |||||
| PE Ratio without NRI | 11.72 | |||||
| Shiller PE Ratio | 5.93 | |||||
| Price-to-Owner-Earnings | 4.23 | |||||
| PS Ratio | 0.3 | |||||
| PB Ratio | 0.53 | |||||
| Price-to-Tangible-Book | 1.31 | |||||
| Price-to-Free-Cash-Flow | 7.66 | |||||
| Price-to-Operating-Cash-Flow | 6.94 | |||||
| EV-to-EBIT | 4.33 | |||||
| EV-to-EBITDA | 3.97 | |||||
| EV-to-Revenue | 0.21 | |||||
| EV-to-FCF | 5.4 | |||||
| Price-to-Projected-FCF | 0.43 | |||||
| Price-to-Median-PS-Value | 0.72 | |||||
| Price-to-Graham-Number | 0.82 | |||||
| Price-to-Net-Current-Asset-Value | 1.77 | |||||
| Earnings Yield (Greenblatt) % | 23.09 | |||||
| FCF Yield % | 13.04 | |||||
| Forward Rate of Return (Yacktman) % | -25.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HAEMATO AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 260.808 | ||
| EPS (TTM) (€) | 1.842 | ||
| Beta | 0.85 | ||
| Volatility % | 47.2 | ||
| 14-Day RSI | 51.33 | ||
| 14-Day ATR (€) | 0.680419 | ||
| 20-Day SMA (€) | 16.01 | ||
| 12-1 Month Momentum % | -3.41 | ||
| 52-Week Range (€) | 15 - 27.8 | ||
| Shares Outstanding (Mil) | 5.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HAEMATO AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HAEMATO AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
HAEMATO AG Frequently Asked Questions
What is HAEMATO AG(HAM:HAEK)'s stock price today?
The current price of HAM:HAEK is €17.00. The 52 week high of HAM:HAEK is €27.80 and 52 week low is €15.00.
When is next earnings date of HAEMATO AG(HAM:HAEK)?
The next earnings date of HAEMATO AG(HAM:HAEK) is .
Does HAEMATO AG(HAM:HAEK) pay dividends? If so, how much?
The Dividend Yield %  of HAEMATO AG(HAM:HAEK) is 7.14% (As of Today), Highest Dividend Payout Ratio of HAEMATO AG(HAM:HAEK) was 1.5. The lowest was 0.57. And the median was 0.87. The  Forward Dividend Yield % of HAEMATO AG(HAM:HAEK) is 7.14%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers